Thus, the upregulation of NKp30 expression, as shown here by the ectopic overexpression, may be an alternative and viable strategy to improve the outcomes of NK cell immunotherapy for patients with cancer, particularly AML, without potential risks of IL-2 infusion. The gene discussed is NCR3; the disease is cancer.